Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PEX010 (psilocybin) reacts agonistically with serotonin (5-hydroxytryptamine) type 2A (5-HT2A) receptors to produce a “mystical-like” hallucinatory effect due to induced frontal hyper-frontality, which in turn mediates its anti-depressant and anti-an...
Brand Name : PEX010
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 15, 2023
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Psyence
Deal Size : $3.0 million
Deal Type : Licensing Agreement
Details : The agreement grants Psyence the worldwide right to commercialize Filament’s natural psilocybin drug candidate, PEX010 (psilocybin), within the context of palliative care.
Brand Name : PEX010
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 15, 2022
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Psyence
Deal Size : $3.0 million
Deal Type : Licensing Agreement
Filament Health Announces First Dosing in Groundbreaking FDA-Approved Psilocin Clinical Trial
Details : The trial, conducted at UCSF’s TrPR Lab, is first to use naturally derived psychedelic drug candidates and first to directly administer PEX010 (psilocin), the active form of psilocybin.
Brand Name : PEX010
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 07, 2022
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Study Phase : IND Enabling
Recipient : Psyence
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Psyence and Filament Health Enter Into Exclusive Licensing Agreement for Natural Psilocybin Products
Details : Under the terms of the agreement, Filament will license its proprietary botanical drug candidate PEX010 (25mg) and the associated IP to Psyence for use in Psyence’s upcoming clinical trials.
Brand Name : PEX010
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 19, 2022
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : IND Enabling
Recipient : Psyence
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?
Reset All
